CD8 TIL cell therapy - Aventis Gencell

Drug Profile

CD8 TIL cell therapy - Aventis Gencell

Latest Information Update: 09 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aventis Gencell
  • Class Cell therapies
  • Mechanism of Action CD8 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Graft-versus-host disease; Renal cancer

Most Recent Events

  • 11 Jan 2000 A study has been added to the therapeutic trials and adverse events sections
  • 24 Dec 1999 Rhône-Poulenc Rorer Gencell is now Aventis Gencell
  • 31 Aug 1998 A study has been added to the therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top